CCG
ABMD

Cypress Capital Group’s Abiomed Inc ABMD Stock Holding History

Cypress Capital Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,051
Closed -$291K – 278
2020
Q3 		$291K Buy
1,051
+9
+0.9% +$2.59K 0.05% 221
2020
Q2 		$252K Buy
+1,042
New +$209K 0.05% 219

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cypress Capital Group's ABMD Position: Q4 2020 in Review

Cypress Capital Group sold out of Abiomed Inc (ABMD) in Q4 2020, closing a stake of 1,051 shares — an estimated $291K sold.

Cypress Capital Group first reported a position in ABMD in Q2 2020 and held it in 2 quarters. The position peaked at $291K in Q3 2020. 498 funds tracked by Wall St. Rank hold ABMD as of Q4 2020.

  • Cypress Capital Group reported no remaining Abiomed Inc position as of Q4 2020 after selling out during the quarter.
  • Cypress Capital Group sold 1,051 Abiomed Inc shares in Q4 2020, an estimated $291K.
  • Cypress Capital Group first reported a position in Abiomed Inc in Q2 2020 and held it in 2 quarters.
  • Cypress Capital Group's Abiomed Inc position peaked at $291K in Q3 2020.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2020.

Based on Cypress Capital Group's 13F filing for Q4 2020, filed 12 Jan 2021.